Ticker League

Free Cash Flow for Vertex Pharmaceuticals (VRTX)

As of · Reported

Metric

Latest period

$3.71B

YoY change

-504.1%

5Y CAGR

+1.3%

Peak year (2022)

$3.93B

Free Cash Flow history chart for Vertex Pharmaceuticals (VRTX) from 1991 to 2025

Latest: $3.19B

Free Cash Flow growth chart for Vertex Pharmaceuticals (VRTX) from 1991 to 2025

Latest: -504.1%

Free Cash Flow history table for Vertex Pharmaceuticals (VRTX) from 1991 to 2025

  • 2025$3.19B-504.1%
  • 2024−$790.30M-124.1%
  • 2023$3.28B-16.5%
  • 2022$3.93B+63.0%
  • 2021$2.41B-19.5%
  • 2020$2.99B+100.4%
  • 2019$1.49B+27.2%
  • 2018$1.17B+100.6%
  • 2017$585.52M+226.1%
  • 2016$179.54M-143.7%
  • 2015−$410.73M-27.2%
  • 2014−$564.40M+448.2%
  • 2013−$102.96M-152.3%
  • 2012$196.70M+300.3%
  • 2011$49.14M-107.3%
  • 2010−$673.50M+49.3%
  • 2009−$451.08M+74.4%
  • 2008−$258.66M-9.2%
  • 2007−$284.89M+419.0%
  • 2006−$54.89M-71.0%
  • 2005−$189.01M+22.2%
  • 2004−$154.66M-16.4%
  • 2003−$184.97M+53.2%
  • 2002−$120.76M+94.9%
  • 2001−$61.97M+117.0%
  • 2000−$28.56M-40.5%
  • 1999−$48.00M+23.1%
  • 1998−$39.00M+153.2%
  • 1997−$15.40M-65.2%
  • 1996−$44.30M+107.0%
  • 1995−$21.40M+28.9%
  • 1994−$16.60M-344.1%
  • 1993$6.80M-200.0%
  • 1992−$6.80M+83.8%
  • 1991−$3.70M—

Free Cash Flow values are taken from Vertex Pharmaceuticals's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About Free Cash Flow at Vertex Pharmaceuticals (VRTX)

Free Cash Flow for Vertex Pharmaceuticals (VRTX): headline value $3.71B · YoY -504.1%. Annual and quarterly series, chart, and tables are below.

Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .

The 2025 reading of Vertex Pharmaceuticals (VRTX) free cash flow is $3.19B – plunged 504.1% year-over-year.

Vertex Pharmaceuticals free cash flow compound annual growth for the 2020–2025 (5 years) window is +1.3%, with mixed annual results across the window.

Vertex Pharmaceuticals free cash flow peaked at $3.93B in 2022; the latest annual figure is $3.19B in 2025 (18.6% below peak).

2022 marks the peak free cash flow at $3.93B, with the historical low of −$790.30M recorded in 2024.

Vertex Pharmaceuticals Free Cash Flow by Year

Vertex Pharmaceuticals Free Cash Flow 2025: $3.19B

Vertex Pharmaceuticals free cash flow in 2025 was $3.19B, plunged 504.1% below 2024.

Vertex Pharmaceuticals Free Cash Flow 2024: −$790.30M

2024's free cash flow for Vertex Pharmaceuticals came in at −$790.30M, plunged 124.1% below 2023. This figure represents the lowest annual value in the available history.

Vertex Pharmaceuticals Free Cash Flow 2023: $3.28B

Vertex Pharmaceuticals posted free cash flow of $3.28B in 2023, declined 16.5% below 2022.

Vertex Pharmaceuticals Free Cash Flow 2022: $3.93B

In 2022, Vertex Pharmaceuticals reported free cash flow of $3.93B, surged 63.0% from 2021. This figure represents the highest annual value in the available history.

Vertex Pharmaceuticals Free Cash Flow 2021: $2.41B

Vertex Pharmaceuticals free cash flow in 2021 was $2.41B.

See more financial history for Vertex Pharmaceuticals (VRTX).

Sector peers by Free Cash Flow

Healthcare peers of Vertex Pharmaceuticals (VRTX), ranked by their latest free cash flow

Frequently asked questions

Vertex Pharmaceuticals (VRTX) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation